Abstract

Purpose

Score reproducibility is an important measurement property of fit-for-purpose patient-reported outcome (PRO) measures. It is commonly assessed via test–retest reliability, and best evaluated with a stable participant sample, which can be challenging to identify in diseases with highly variable symptoms. To provide empirical evidence comparing the retrospective (patient global impression of change [PGIC]) and current state (patient global impression of severity [PGIS]) approaches to identifying a stable subgroup for test–retest analyses, 3 PRO Consortium working groups collected data using both items as anchor measures.

Methods

The PGIS was completed on Day 1 and Day 8 + 3 for the depression and non-small cell lung cancer (NSCLC) studies, and daily for the asthma study and compared between Day 3 and 10. The PGIC was completed on the final day in each study. Scores were compared using an intraclass correlation coefficient (ICC) for participants who reported “no change” between timepoints for each anchor.

Results

ICCs using the PGIS “no change” group were higher for depression (0.84 vs. 0.74), nighttime asthma (0.95 vs. 0.53) and daytime asthma (0.86 vs. 0.68) compared to the PGIC “no change” group. ICCs were similar for NSCLC (PGIS: 0.87; PGIC: 0.85).

Conclusion

When considering anchor measures to identify a stable subgroup for test–retest reliability analyses, current state anchors perform better than retrospective anchors. Researchers should carefully consider the type of anchor selected, the time period covered, and should ensure anchor content is consistent with the target measure concept, as well as inclusion of both current and retrospective anchor measures.

Details

Title
Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures
Author
Eremenco, Sonya 1   VIAFID ORCID Logo  ; Chen, Wen-Hung 2 ; Blum, Steven I. 3 ; Bush, Elizabeth Nicole 4 ; Bushnell, Donald M. 5 ; DeBusk, Kendra 6 ; Gater, Adam 7 ; Nelsen, Linda 2 ; Coons, Stephen Joel 1   VIAFID ORCID Logo 

 Critical Path Institute, Tucson, USA (GRID:grid.417621.7) 
 GlaxoSmithKline, Collegeville, USA (GRID:grid.418019.5) (ISNI:0000 0004 0393 4335) 
 Bristol Myers Squibb, Lawrenceville, USA (GRID:grid.419971.3) (ISNI:0000 0004 0374 8313) 
 Eli Lilly and Company, Indianapolis, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544) 
 Evidera | PPD, Phoenix, USA (GRID:grid.417540.3) 
 Seagen Inc, Bothell, USA (GRID:grid.417540.3) 
 Adelphi Values, Bollington, UK (GRID:grid.417540.3) 
Pages
3501-3512
Publication year
2022
Publication date
Dec 2022
Publisher
Springer Nature B.V.
ISSN
09629343
e-ISSN
15732649
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2727283081
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.